Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

CONCLUSIONS: PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.PMID:38236575 | DOI:10.1158/1078-0432.CCR-23-2513

Source: Clinical Cancer Research - January 18, 2024 Category: Cancer & Oncology Authors: Tira J Tan Sarah Sammons Young-Hyuck Im Lilin She Kelly Mundy Robert Bigelow Tiffany A Traina Carey Anders Joe Yeong Ezequiel Renzulli Sung-Bae Kim Rebecca Dent Source Type: research